ABSTRACT
Oxidative stress is thought to play a major role in the pathogenesis of Alzheimer's disease (AD). Although there is strong post-mortem and experimental evidence of oxidative damage occurring in AD brains, the use of markers in the peripheral circulation to show oxidative stress is less convincing. We examined plasma from AD patients for markers of increased oxidative stress. We report elevated levels of 4-hydroxy-nonenal (4-HNE) in AD patients compared to controls (median 20.6, IQR 6.0-25.2 vs. 7.8, 3.3-14.5 micomol/l, respectively; p=0.001) but not malondialdehyde (MDA), and lower levels of ascorbate in AD plasma when compared to age-matched controls (9.9, 6.0-33.7 vs. 24.2, 13.9-48.6 micromol/l; p<0.05). Levels of 4-HNE in AD patients were inversely related to ascorbate (r=-0.337; p=0.07) and Folstein Mini-Mental State Examination (MMSE) (r=-0.474; p=0.015). The concentration of protein sulphydryls, free-radical scavengers, was directly related to the MMSE result (r=0.427; p=0.03). Increased production of 4-HNE indicates increased oxidative stress (lipid peroxidation), which is not evident using the more common marker MDA. This elevation of 4-HNE was related to the degree of cognitive impairment (MMSE).
Subject(s)
Aldehydes/blood , Alzheimer Disease/metabolism , Malondialdehyde/blood , Oxidative Stress/physiology , Aged , Aged, 80 and over , Alzheimer Disease/etiology , Ascorbic Acid/blood , Biomarkers/blood , Case-Control Studies , Chromatography, High Pressure Liquid , Female , Humans , Linear Models , Male , Middle Aged , Normal Distribution , Nutrition Assessment , Psychological Tests , Spectrophotometry , Statistics, Nonparametric , Sulfhydryl Compounds/bloodABSTRACT
In view of accumulating evidence of vascular pathology in Alzheimer's disease (AD), we tested the hypothesis that AD patients have impaired endothelial function. This was assessed using the technique of strain-gauge venous occlusion plethysmography, which measures forearm blood flow (FBF). Intra-arterial (brachial) infusion of acetylcholine (ACh) and sodium nitroprusside (SNP) was used to assess local endothelial dependent and independent responses, respectively. There was no difference in the basal FBF of patients and controls. ACh and SNP caused dose-related increases in FBF from baseline, but no difference was recorded between the AD and control group. This study provides no evidence of endothelial dysfunction in the systemic circulation of patients with AD.
Subject(s)
Alzheimer Disease/physiopathology , Brachial Artery/drug effects , Endothelium, Vascular/drug effects , Vasodilator Agents/pharmacology , Acetylcholine/administration & dosage , Acetylcholine/pharmacology , Aged , Aged, 80 and over , Alzheimer Disease/complications , Case-Control Studies , Dose-Response Relationship, Drug , Endothelium, Vascular/physiopathology , Female , Forearm/blood supply , Humans , Infusions, Intra-Arterial , Male , Middle Aged , Nitroprusside/administration & dosage , Nitroprusside/pharmacology , Plethysmography/methods , Regional Blood Flow/drug effects , Vascular Diseases/complications , Vascular Diseases/physiopathologyABSTRACT
Alzheimer's disease (AD) is a progressive neurodegenerative disorder that has been associated, sometimes controversially, with polymorphisms in a number of genes. Recently the butyrylcholinesterase K variant (BCHE K) allele has been shown to act in synergy with the apolipoprotein E epsilon4 (APOE epsilon4) allele to promote risk for AD. Most subsequent replicative studies have been unable to confirm these findings. We have conducted a case-control association study using a clinically well defined group of late onset AD patients (n=175) and age and sex matched control subjects (n=187) from the relatively genetically homogeneous Northern Ireland population to test this association. The BCHE genotypes of patients were found to be significantly different from controls (chi(2)=23.68, df=2, p<<0.001). The frequency of the K variant allele was also found to differ significantly in cases compared to controls (chi(2)=16.39, df=1, p<<0.001) leading to an increased risk of AD in subjects with this allele (OR=3.50, 95% CI 2. 20-6.07). This risk increased in subjects 75 years and older (OR=5. 50, 95% CI 2.56-11.87). At the same time the APOE epsilon4 associated risk was found to decrease from 6.70 (95% CI 2.40-19.04) in 65-74 year olds to 3.05 (95% CI 1.34-6.95) in those subjects 75 years and older. However, we detected no evidence of synergy between BCHE K and APOE epsilon4. The results from this study suggest that possession of the BCHE K allele constitutes a significant risk for AD in the Northern Ireland population and, furthermore, this risk increases with increasing age.
Subject(s)
Alzheimer Disease/genetics , Butyrylcholinesterase/genetics , Genetic Variation , Age of Onset , Aged , Aged, 80 and over , Alleles , Alzheimer Disease/ethnology , Apolipoprotein E4 , Apolipoproteins E/genetics , Case-Control Studies , Female , Gene Frequency , Genotype , Humans , Male , Middle Aged , Northern IrelandABSTRACT
It has recently been reported that a genetic polymorphism in exon 2 of the cathepsin D gene conferred increased risk for development of Alzheimer's disease (AD). Because of the potential importance of this report we tested this association in a clinically well-defined group of AD patients and age and sex matched control subjects from the relatively genetically homogeneous Northern Ireland population. This study failed to confirm the reported association between the cathepsin D exon 2 polymorphism and AD. We conclude that if an association exists between this polymorphism and AD it is likely to be small.
